Receptors in the management of breast cancer.
Assay of breast cancers for oestrogen receptors helps to select advanced cases (about 30%) who will benefit from milder (endocrine) therapy, and, in early disease, gauge overall survival and likelihood of benefit from adjuvant endocrine therapy. A reliable immunocytochemical assay for receptor, now available, should extend the usefulness of such measurements.
R A
RA
Hawkins
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000032:analysis* / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D003911:Dextrans; D005260:Female; D006801:Humans; D008722:Methods; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*
D000970:Antineoplastic Agents; D003911:Dextrans; D011960:Receptors, Estrogen